FY2020 EPS Estimates for Kalvista Pharmaceuticals Inc Increased by Cantor Fitzgerald (NASDAQ:KALV)

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) – Equities researchers at Cantor Fitzgerald raised their FY2020 EPS estimates for shares of Kalvista Pharmaceuticals in a research report issued on Wednesday, October 16th. Cantor Fitzgerald analyst C. Duncan now anticipates that the specialty pharmaceutical company will post earnings per share of ($2.08) for the year, up from their prior forecast of ($2.73).

Kalvista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Monday, September 9th. The specialty pharmaceutical company reported ($0.42) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.20. The company had revenue of $3.37 million during the quarter, compared to analyst estimates of $3.24 million. Kalvista Pharmaceuticals had a negative net margin of 144.64% and a negative return on equity of 22.29%.

Several other analysts have also recently issued reports on the stock. TheStreet cut shares of Kalvista Pharmaceuticals from a “c-” rating to a “d+” rating in a research report on Thursday, July 11th. Svb Leerink started coverage on shares of Kalvista Pharmaceuticals in a research report on Monday, July 29th. They set an “outperform” rating and a $31.00 price target on the stock. BidaskClub cut shares of Kalvista Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 6th. Leerink Swann started coverage on shares of Kalvista Pharmaceuticals in a research report on Monday, July 29th. They set an “outperform” rating and a $31.00 price target on the stock. Finally, Zacks Investment Research raised shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research report on Wednesday, September 18th. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $29.43.

Shares of KALV opened at $11.03 on Monday. The stock has a market capitalization of $204.40 million, a PE ratio of -7.99 and a beta of 2.07. Kalvista Pharmaceuticals has a 1 year low of $9.86 and a 1 year high of $34.92. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.29 and a current ratio of 8.29. The company’s 50-day simple moving average is $12.85 and its 200-day simple moving average is $18.67.

In other Kalvista Pharmaceuticals news, Director Albert Cha purchased 26,500 shares of Kalvista Pharmaceuticals stock in a transaction dated Friday, July 26th. The shares were acquired at an average price of $16.83 per share, with a total value of $445,995.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have bought 84,905 shares of company stock worth $1,427,923 in the last three months. Corporate insiders own 21.60% of the company’s stock.

A number of large investors have recently modified their holdings of KALV. Cubist Systematic Strategies LLC acquired a new stake in Kalvista Pharmaceuticals in the second quarter valued at approximately $42,000. Strs Ohio acquired a new stake in Kalvista Pharmaceuticals in the second quarter valued at approximately $68,000. Marshall Wace North America L.P. acquired a new stake in Kalvista Pharmaceuticals in the first quarter valued at approximately $175,000. Virtus ETF Advisers LLC acquired a new stake in Kalvista Pharmaceuticals in the second quarter valued at approximately $297,000. Finally, Swiss National Bank acquired a new stake in Kalvista Pharmaceuticals in the second quarter valued at approximately $390,000. 82.98% of the stock is currently owned by hedge funds and other institutional investors.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Recommended Story: What are the Benefits of Index Funds?

Earnings History and Estimates for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit